EGFR and non-small cell lung carcinoma: Particularly in EGFR-mutated NSCLC, treatment with first-line tyrosine kinase inhibitors (TKI) frequently results in the development of primary and secondary resistance mutations (e.g., EGFR p.(T790M) and EGFR p.(C797S), respectively) that might act as targets for other treatment options [11,12].